Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
It is desirable to find more appropriate therapeutic opportunities in non-small-cell lung cancer (NSCLC) due to the current poor prognosis of affected patients. Recently, several histone deacetylase (HDAC) inhibitors, including suberoylanilide hydroxamic acid (SAHA), have been reported to exhibit antitumor activities against NSCLC. S-1, a novel oral fluorouracil anticancer drug, has been developed for clinical use in the treatment of NSCLC in Japan. Using an MTT assay, we analyzed the growth-inhibitory effect of 5-fluorouracil (5-FU), S-1, and SAHA against three NSCLC cell lines, as well as the breast cancer cell line MCF7 which is known to be highly sensitive to 5-FU. Combined treatment with low-dose SAHA enhanced 5-FU- and S-1-mediated cytotoxicity and resulted in synergistic effects, especially in 5-FU-resistant cells. Both the mRNA and protein expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and orotate phosphoribosyltransferase (OPRT), which are associated with 5-FU sensitivity/response, were analyzed in the cells undergoing treatment. 5-Fluorouracil-resistant lung cancer cells displayed high expression of TS mRNA and protein. Suberoylanilide hydroxamic acid down-regulated TS mRNA and protein expression, as well as repressed the rapid induction of this factor during 5-FU treatment, in all examined cell types. We also examined the status of the Rb-E2F1 pathway, with SAHA up-regulating p21(waf1/cip1) expression via promoter histone acetylation; this, in turn, blocked the Rb-E2F1 pathway. We conclude that combination therapy with SAHA and S-1 in lung cancer may be promising due to its potential to overcome S-1 resistance via modulation of 5-FU/S-1 sensitivity-associated biomarker (TS) by HDAC inhibitor.
Noro
Rintaro
R
Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Miyanaga
Akihiko
A
Minegishi
Yuji
Y
Okano
Tetsuya
T
Seike
Masahiro
M
Soeno
Chie
C
Kataoka
Kiyoko
K
Matsuda
Kuniko
K
Yoshimura
Akinobu
A
Gemma
Akihiko
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000096:biosynthesis*; D004338:Drug Combinations; D050687:E2F1 Transcription Factor / Q000378:metabolism; D005472:Fluorouracil / Q000008:administration & dosage; D005786:Gene Expression Regulation / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010094:Oxonic Acid / Q000008:administration & dosage; D012333:RNA, Messenger / Q000032:analysis; D016160:Retinoblastoma Protein / Q000378:metabolism; D005641:Tegafur / Q000008:administration & dosage; D013940:Thymidylate Synthase / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics; D000077337:Vorinostat
C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D004338:Drug Combinations; D050687:E2F1 Transcription Factor; C493753:E2F1 protein, human; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D012333:RNA, Messenger; D016160:Retinoblastoma Protein; C079198:S 1 (combination); D005641:Tegafur; D000077337:Vorinostat; D010094:Oxonic Acid; D013940:Thymidylate Synthase; D005472:Fluorouracil
Clin Cancer Res. 2000 Jun;6(6):2538-46
10873110
Clin Cancer Res. 2004 Dec 1;10(23):7860-4
15585618
Br J Cancer. 2006 Sep 4;95(5):607-15
16880781
J Clin Oncol. 2000 Jan;18(1):122-30
10623702
Br J Cancer. 2001 Sep 28;85(7):939-43
11592762
Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S80-9
12819937
Clin Cancer Res. 2006 Dec 1;12(23):7039-45
17145826
Clin Cancer Res. 2007 Dec 1;13(23):6938-46
18056168
Cancer Res. 1998 Oct 1;58(19):4292-6
9766655
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88
14506144
BMJ. 1995 Oct 7;311(7010):899-909
7580546
Cancer Biol Ther. 2009 May;8(9):782-91
19270508
Eur J Cancer. 1995 Jul-Aug;31A(7-8):1299-305
7577040
J Immunol. 2008 Mar 1;180(5):3218-28
18292546
N Engl J Med. 2005 Jul 14;353(2):123-32
16014882
J Clin Oncol. 2000 Jul;18(14):2772-9
10894878
Cancer Res. 1986 Jan;46(1):20-8
2415245
J Clin Oncol. 2005 Jun 10;23(17):3923-31
15897550
Oncogene. 2004 Mar 4;23(9):1724-36
14676837
Mol Cell Biol. 1995 Aug;15(8):4215-24
7623816
Future Oncol. 2006 Apr;2(2):289-99
16563096
Int J Cancer. 2003 Sep 1;106(3):324-6
12845668
Mol Cancer Ther. 2008 Jul;7(7):1923-30
18606719
Eur J Cancer. 2001 Aug;37(12):1554-61
11506965
J Clin Oncol. 1997 Jan;15(1):389-400
8996166
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
10954755
Cancer Res. 2000 May 1;60(9):2365-7
10811110
Clin Cancer Res. 2000 Jul;6(7):2707-11
10914714
Cancer Res. 1993 Sep 1;53(17):4004-9
7689420
Cancer Res. 2003 Nov 1;63(21):7291-300
14612526
Lung Cancer. 2005 Jul;49(1):47-54
15949589
Blood. 2007 Jan 1;109(1):31-9
16960145
J Clin Oncol. 2000 May;18(10):2095-103
10811675
Oncol Rep. 2006 Mar;15(3):545-9
16465410
Nat Rev Drug Discov. 2002 Apr;1(4):287-99
12120280
BMC Cancer. 2006 Dec 06;6:277
17150102
Cancer. 2004 Dec 15;101(12):2760-70
15536623
Cancer Res. 2004 Nov 15;64(22):8167-76
15548681
J Cell Biochem. 2004 May 15;92(2):223-37
15108350
J Clin Oncol. 2004 May 1;22(9):1589-97
15117980
Clin Cancer Res. 2001 Jul;7(7):2114-23
11448931